Novartis Venture Fund

Novartis Venture Fund operates as the strategic investment arm of Novartis, one of the world's leading pharmaceutical companies dedicated to reimagining medicine through innovation. Established to support breakthrough healthcare solutions, the fund identifies and backs promising biotech startups, emerging healthcare technologies, and novel therapeutic approaches that align with Novartis' mission to improve and extend human lives. With a global investment portfolio, the fund leverages Novartis' scientific expertise and industry connections to provide more than just capital to its portfolio companies.

The investment strategy of Novartis Venture Fund focuses primarily on early to mid-stage companies developing cutting-edge therapeutics and technologies across multiple disease areas. The fund typically participates in Series A and B financing rounds, though it maintains flexibility to engage at various stages of company development. Beyond financial support, portfolio companies benefit from Novartis' extensive R&D infrastructure, regulatory expertise, and global commercialization capabilities, creating a powerful ecosystem for healthcare innovation acceleration.

With investments spanning North America, Europe, and emerging biotech hubs globally, the fund has built an impressive track record of supporting companies that have delivered significant medical advances. Many of these portfolio companies have successfully developed treatments reaching millions of patients worldwide, reflecting Novartis' broader impact where their medicines touch more than 250 million lives annually. The fund's investment decisions are guided by both financial return potential and strategic alignment with Novartis' core therapeutic areas, including oncology, immunology, neuroscience, and cardiovascular medicine.

As part of its commitment to healthcare transformation, Novartis Venture Fund actively engages with the broader innovation ecosystem through partnerships with academic institutions, research foundations, and other venture investors. This collaborative approach helps identify emerging scientific breakthroughs with potential to address unmet medical needs. The fund operates with a long-term perspective, recognizing that developing meaningful healthcare solutions requires sustained commitment. This patient capital approach, combined with Novartis' scientific credibility and global healthcare expertise, positions the fund as a valuable partner for entrepreneurs working to create the next generation of life-changing medical innovations.